Log in

NASDAQ:ACHNAchillion Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$6.76
MA: $6.76
$6.76
52-Week Range N/A
VolumeN/A
Average Volume8.44 million shs
Market Capitalization$946.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Read More
Achillion Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.92 per share

Profitability

Net Income$-70,270,000.00

Miscellaneous

Employees56
Market Cap$946.72 million
Next Earnings DateN/A
OptionableOptionable

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Achillion Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Achillion Pharmaceuticals.

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) posted its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.02. View Achillion Pharmaceuticals' earnings history.

What price target have analysts set for ACHN?

2 analysts have issued 12 month price targets for Achillion Pharmaceuticals' shares. Their forecasts range from $6.30 to $6.30. On average, they expect Achillion Pharmaceuticals' share price to reach $6.30 in the next twelve months. View analysts' price targets for Achillion Pharmaceuticals.

Has Achillion Pharmaceuticals been receiving favorable news coverage?

Media stories about ACHN stock have been trending extremely negative on Wednesday, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of -4.6 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAchillion Pharmaceuticals.

Who are some of Achillion Pharmaceuticals' key competitors?

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Iconix Brand Group (ICON), ACADIA Pharmaceuticals (ACAD), Celldex Therapeutics (CLDX) and Edap Tms (EDAP).

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the following people:
  • Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
  • Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
  • Mr. Brian R. Di Donato, CFO, SVP & Treasurer (Age 52)
  • Mr. Paul Firuta, Exec. VP & COO (Age 53)
  • Dr. Kevin P. Malobisky, Sr. VP of Regulatory Affairs, Quality & Compliance

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $0.00. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.

What is Achillion Pharmaceuticals' official website?

The official website for Achillion Pharmaceuticals is www.achillion.com.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.